2023-510479-72-00暂停1 期
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 入组人数
- 20
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Ignasi Riera
Scientific
Remix Therapeutics Inc.
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.2023-508476-11-00Remix Therapeutics Inc.30
进行中（未招募）
1 期
A trial to investigate the safety and tolerability of E7046 when it is given together with radiation and chemotherapy before surgery in patients who have rectum cancer.EUCTR2016-003064-38-GBAdlai Nortye USA Inc35
进行中（未招募）
1 期
A trial to investigate the safety and tolerability of E7046 when it is given together with radiation and chemotherapy before surgery in patients who have rectum cancer.ocally advanced rectum cancerMedDRA version: 20.0Level: LLTClassification code 10007464Term: Carcinoma rectumSystem Organ Class: 100000004864EUCTR2016-003064-38-PLAdlai Nortye USA INC.35
招募中
1 期
A study of RMC-6291 in combination with pembrolizumab in participants with solid tumors with certain mutations- Subprotocol Aung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-509571-16-00Revolution Medicines Inc.345
招募中
1 期
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmallcell lung cancer with certain mutations -Subprotocol Bung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-509572-42-00Revolution Medicines Inc.405